<DOC>
	<DOC>NCT00337649</DOC>
	<brief_summary>This single arm study will determine the efficacy and safety of an epothilone D and Herceptin combination regimen in patients with HER-2 positive locally advanced or metastatic breast cancer. Epothilone D will be administered intravenously on days 1, 8 and 15 every 4 weeks at a dose not exceeding 100mg/m2. Herceptin will be administered intravenously on a weekly schedule; a 4mg/kg loading dose will be followed by a weekly maintenance dose of 2mg/kg. The anticipated time on study treatment is until disease progression, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer.</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>women &gt;=18 years; locally advanced or metastatic breast cancer; HER2 overexpression (FISH + or IHC 3+); &gt;=1 measurable lesion; up to one prior anthracyclinebased chemotherapy regimen in a metastatic setting. preexisting neuropathy &gt;=grade 2; known CNS metastases; congestive heart failure, or myocardial infarction within the last 6 months; previous malignancies in last 5 years, except for cured basal cell cancer of the skin, or cancer in situ of the cervix.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>